SUPERSTRING CAPITAL MANAGEMENT LP
Adviser information for SUPERSTRING CAPITAL MANAGEMENT LP last updated from Form ADV on March 28th, 2024. Select data displayed; additional Form ADV, Form D, Form 13F and other data is available from the Fincoded API.
Advisory Business
Type of Organization | Limited Partnership |
---|---|
Fiscal Year End | DECEMBER |
Legal Location | Delaware, United States |
Employees
Total Number of Employees | 6 |
---|---|
Investment Advisory/Research | 4 |
Registered Broker-Dealer Representatives | 0 |
Registered State Investment Advisers | 0 |
Licensed Agents of an Insurance Company | 0 |
No. of Firms/People that Solicit Clients | 0 |
RAUM
Provides Management of Securities Portfolios | Yes |
---|
Type | Accounts | RAUM |
---|---|---|
Discretionary | 8 | $371.1M |
Non-Discretionary | 0 | $0 |
Total | 8 | $371.1M |
Clients
Type | Number | RAUM |
---|---|---|
Individuals | 0 | $0 |
HNW Individuals | 0 | $0 |
Banking or thrift institutions | 0 | $0 |
Investment companies | 0 | $0 |
Business development companies | 0 | $0 |
Pooled investment vehicles | 5 | $307.4M |
Pension and profit sharing plans | 0 | $0 |
Charitable organizations | 0 | $0 |
State or municipal gov entities | 0 | $0 |
Other investment advisers | 0 | $0 |
Insurance companies | 0 | $0 |
Sovereign wealth funds and foreign official institutions | 0 | $0 |
Corporations or other businesses | 0 | $0 |
Other | 3 | $63.7M |
Type | Number |
---|---|
No. of Non-RAUM Clients | 0 |
No. of Non-U.S. Clients | 60 |
Services
Advisory Services | Portfolio management for pooled investment vehiclesSEPARATELY MANAGED ACCOUNTS |
---|---|
Compensation | % of AUMPerformance-based fees |
Other Business Activities | Commodity pool operator or commodity trading advisor |
Principal Office
150 E 52ND STSUITE 5004
NEW YORK
NY
United States
Monday - Friday, 9-5
Tel: 212-257-5690, Fax: None
Websites
Chief Compliance Officer
GEORGE SONG
COO/CFO
150 E 52ND STREET
SUITE 5004
NEW YORK
NY
United States
Tel:
212-257-5690
G****@*****************M
(Full email address available in API data)
Industry Affiliates
SUPERSTRING CAPITAL FUND GP LLC | Sponsor, GP, manager of pooled investment vehicles |
Private Funds
Name | Type | Assets $USD | Min Investment $USD | No. Owners |
---|---|---|---|---|
SUPERSTRING CAPITAL MASTER FUND LP | Hedge Fund | $258.5M | $5.0M | 60 |
SUPERSTRING PRIVATE OPPORTUNITES FUND I LP | Private Equity Fund | $48.9M | $1.0M | 16 |
Control Persons
Name | Type | Entity | Title | Since | Ownership |
---|---|---|---|---|---|
SUPERSTRING CAPITAL FUND GP LLC | Domestic Entity | – | GENERAL PARTNER | 10/2019 | < 5% |
Ting, Guo | Individual | – | MANAGING PARTNER | 10/2019 | > 75% |
Ting, Guo | Individual | SUPERSTRING CAPITAL FUND GP LLC | MANAGING PARTNER | 10/2019 | > 75% |
SONG, GEORGE, BENEDICT | Individual | – | CHIEF COMPLIANCE OFFICER, CHIEF OPERATING OFFICER, CHIEF FINANCIAL OFFICER | 10/2019 | < 5% |
No. Employees, Historic
RAUM, Historic
No. Clients, Historic
Holdings
From latest 13F, filed August 14th, 2024 for period ending June 30th, 2024
Name | Class | Value $USD | # Shares | Private Fund |
---|---|---|---|---|
89BIO INC | COM | 5M | 680K | – |
ALLAKOS INC | COM | 941K | 941K | – |
ALLOGENE THERAPEUTICS INC | COM | 2M | 690K | – |
APOGEE THERAPEUTICS INC | COM | 1M | 37K | – |
ARCELLX INC | COMMON STOCK | 3M | 59K | – |
ARROWHEAD PHARMACEUTICALS IN | COM | 3M | 111K | – |
ATYR PHARMA INC | COM NEW | 488K | 313K | – |
BEIGENE LTD | SPONSORED ADR | 2M | 13K | – |
BIOMEA FUSION INC | COM | 752K | 167K | – |
BRIDGEBIO PHARMA INC | COM | 6M | 220K | – |
CABALETTA BIO INC | COM | 1M | 140K | – |
COMPASS PATHWAYS PLC | SPONSORED ADS | 196K | 32K | – |
CORBUS PHARMACEUTICALS HLDGS | COM NEW | 3M | 56K | – |
CYTOKINETICS INC | COM NEW | 10M | 188K | – |
CYTOMX THERAPEUTICS INC | COM | 1M | 1M | – |
EYEPOINT PHARMACEUTICALS INC | COM NEW | 329K | 38K | – |
FATE THERAPEUTICS INC | COM | 2M | 497K | – |
KARYOPHARM THERAPEUTICS INC | COM | 464K | 534K | – |
KEROS THERAPEUTICS INC | COM | 3M | 74K | – |
KURA ONCOLOGY INC | COM | 746K | 36K | – |
LAKESHORE BIOPHARMA CO LTD | ORDINARY SHARES | 200K | 308K | – |
LEGEND BIOTECH CORP | SPONSORED ADS | 7M | 155K | – |
MARINUS PHARMACEUTICALS INC | COM NEW | 306K | 262K | – |
MERSANA THERAPEUTICS INC | COM | 221K | 110K | – |
NEWAMSTERDAM PHARMA COMPANY | ORDINARY SHARES | 1M | 64K | – |
NKARTA INC | COM | 5M | 876K | – |
NOVOCURE LTD | ORD SHS | 1M | 67K | – |
PEPGEN INC | COM | 467K | 29K | – |
PERSPECTIVE THERAPEUTICS INC | COM NEW | 874K | 88K | – |
PYXIS ONCOLOGY INC | COMMON STOCK | 2M | 484K | – |
SAVARA INC | COM | 806K | 200K | – |
SPRUCE BIOSCIENCES INC | COM | 40K | 78K | – |
SPYRE THERAPEUTICS INC | COM NEW | 1M | 46K | – |
SYROS PHARMACEUTICALS INC | COM NEW | 195K | 38K | – |
TANGO THERAPEUTICS INC | COM | 992K | 116K | – |
TERNS PHARMACEUTICALS INC | COM | 7M | 957K | – |
TOURMALINE BIO INC | COM | 1M | 95K | – |
ZAI LAB LTD | ADR | 4M | 215K | – |
ZURA BIO LTD | CLASS A ORD SHS | 548K | 157K | – |